On June 28, the NMPA said it plans to improve services to foreign medical companies. Primarily, this message is to further help foreign drug and medical device companies with more efficient product registration. Their focus will be primarily on the pediatric and rare disease drug areas and innovative medical devices. In early 2020, China drafted a patent linkage system to protect intellectual property, patient rights, etc., but this legislation has not been implemented yet. Another upgrade will include better communication with foreign applicants including better education on what the requirements are. While the NMPA wants to clarify and make more transparent issues that have been raised in the past, whether these efforts will be successful remains to be seen.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.
Source used in the article: https://itif.org/publications/2019/08/12/chinas-biopharmaceutical-strategy-challenge-or-complement-us-industry/